MA47137B1 - Pd-1 and lag-3 binding molecules and their methods of use - Google Patents
Pd-1 and lag-3 binding molecules and their methods of useInfo
- Publication number
- MA47137B1 MA47137B1 MA47137A MA47137A MA47137B1 MA 47137 B1 MA47137 B1 MA 47137B1 MA 47137 A MA47137 A MA 47137A MA 47137 A MA47137 A MA 47137A MA 47137 B1 MA47137 B1 MA 47137B1
- Authority
- MA
- Morocco
- Prior art keywords
- mab
- binding
- antibodies
- methods
- molecules
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des anticorps anti-pd-1 sélectionnés capables de se lier à la fois au pd-1 de singe cynomolgus et au pd-1 humain : pd-1 mab 1, pd-1 mab 2, pd-1 mab 3, pd- 1 mab 4, pd-1 mab 5, pd-1 mab 6, pd-1 mab 7, pd-1 mab 8, pd-1 mab 9, pd-1 mab 10, pd-1 mab 11, pd-1 mab 12, mab pd-1 13, mab pd-1 14 ou mab pd-1 15, et aux versions humanisées et chimériques de ces anticorps. L'invention concerne en outre des molécules se liant à pd-1 qui comprennent des fragments se liant à pd-1 de tels anticorps anti-pd-1, des immunocongugates et des molécules bispécifiques, y compris des diabodies, des bite, des anticorps bispécifiques, etc., qui comprennent (i) de tels fragments se liant à pd-1, et (ii) un domaine capable de lier un épitope d'une molécule impliquée dans la régulation d'un point de contrôle immunitaire présent à la surface d'une cellule immunitaire. La présente invention concerne également des procédés d'utilisation de molécules qui se lient à pd-1 pour stimuler des réponses immunitaires, ainsi que des procédés de détection de pd-1.The present invention relates to selected anti-pd-1 antibodies capable of binding to both cynomolgus monkey pd-1 and human pd-1: pd-1 mab 1, pd-1 mab 2, pd-1 mab 3 , pd- 1 mab 4, pd-1 mab 5, pd-1 mab 6, pd-1 mab 7, pd-1 mab 8, pd-1 mab 9, pd-1 mab 10, pd-1 mab 11, pd -1 mab 12, mab pd-1 13, mab pd-1 14 or mab pd-1 15, and humanized and chimeric versions of these antibodies. The invention further relates to pd-1 binding molecules which comprise pd-1 binding fragments of such anti-pd-1 antibodies, immunocongugates and bispecific molecules, including diabodies, bite, antibodies. bispecific, etc., which include (i) such fragments binding to pd-1, and (ii) a domain capable of binding an epitope of a molecule involved in the regulation of an immune checkpoint present on the surface of an immune cell. The present invention also relates to methods of using molecules that bind to pd-1 to stimulate immune responses, as well as methods of detecting pd-1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198867P | 2015-07-30 | 2015-07-30 | |
| US201562239559P | 2015-10-09 | 2015-10-09 | |
| US201562255140P | 2015-11-13 | 2015-11-13 | |
| US201662322974P | 2016-04-15 | 2016-04-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA47137A MA47137A (en) | 2019-10-30 |
| MA47137B1 true MA47137B1 (en) | 2021-08-31 |
Family
ID=60244687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47137A MA47137B1 (en) | 2015-07-30 | 2016-07-28 | Pd-1 and lag-3 binding molecules and their methods of use |
Country Status (2)
| Country | Link |
|---|---|
| AR (2) | AR105520A1 (en) |
| MA (1) | MA47137B1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019301315A1 (en) * | 2018-07-11 | 2021-02-11 | Kahr Medical Ltd. | PD1-4-1BBL variant fusion protein and methods of use thereof |
| CN116854820B (en) * | 2023-06-26 | 2024-02-06 | 华中科技大学同济医学院附属协和医院 | PD-1 non-blocking scavenging antibodies and uses thereof |
-
2016
- 2016-07-28 MA MA47137A patent/MA47137B1/en unknown
- 2016-07-28 AR ARP160102301A patent/AR105520A1/en unknown
-
2020
- 2020-09-29 AR ARP200102705A patent/AR120117A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR105520A1 (en) | 2017-10-11 |
| MA47137A (en) | 2019-10-30 |
| AR120117A2 (en) | 2022-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42542B1 (en) | Molecules Binding to pd-1 and Corresponding Methods of Use | |
| PH12017502222A1 (en) | Lag-3-binding molecules and methods of use thereof | |
| MA42530B1 (en) | Constructions of Bispecific Antibodies Binding to dll3 and cd3 | |
| MA42622B1 (en) | LIAISONS IN TIGIT AND THEIR USES | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| MA49599A1 (en) | Antibodies specific to cd47 and pd-l1 | |
| EA202092825A1 (en) | ANTI-SIRPA ANTIBODIES AND METHODS OF THEIR APPLICATION | |
| MA43028B1 (en) | Bispecific antibodies for pd1 and tim3 | |
| MA40801A1 (en) | Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123 | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| EP3572430A3 (en) | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent | |
| MA35620B1 (en) | Compositions for the treatment of rheumatoid arthritis and methods of using the same | |
| MA35740B1 (en) | Compositions and methods for antibodies targeting the factor p | |
| MA38161A1 (en) | Anti-bmp-6 Antibody | |
| MA47137B1 (en) | Pd-1 and lag-3 binding molecules and their methods of use | |
| EA202090579A1 (en) | PD-1-BINDING MOLECULES AND METHODS OF THEIR APPLICATION | |
| MY188871A (en) | Pd-1-binding molecules and methods of use thereof | |
| MA41666A1 (en) | Anti-ox40 antibodies and their uses | |
| MA39751B1 (en) | Antibody compositions for the treatment of tumors | |
| MA39559A1 (en) | Glucocorticoid Induced Tumor Necrosis Factor Receptor Antibody (gitr) and their Uses | |
| MA37523B1 (en) | St2 antigen binding protein | |
| MA56083B1 (en) | HUMAN ANTIBODIES AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS MONOCLONAL PIC PROTEIN | |
| MA38503A1 (en) | Anti-il-33 antibodies and their uses |